Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2006-05-18 09:03:34 UTC
Update Date2022-03-07 02:49:11 UTC
HMDB IDHMDB0001938
Secondary Accession Numbers
  • HMDB01938
Metabolite Identification
Common NameLisinopril
DescriptionOne of the Angiotensin-converting enzyme inhibitors (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. -- Pubchem; Lisinopril is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure and heart attacks. Historically, lisinopril was the third ACE inhibitor, after captopril and enalapril that was introduced into therapy in early 1990s. Lisinopril has a number of properties that distinguish it from other ACE inhibitors: it is hydrophilic, has long half life and tissue penetration and is not metabolized by the liver. -- Wikipedia ; Lisinopril is solely excreted in urine in the unchanged form. Elimination of the drug depends on glomerular filtration and tubular excretion. Rate of lisinopril elimination decreases with old age and kidney or heart failure. There is a relation between creatinine and lisinopril clearance. With prolonged therapy dose reduction can be necessary to avoid accumulation. -- Wikipedia .
Structure
Data?1582752218
Synonyms
ValueSource
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-prolineChEBI
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-prolineChEBI
Lisinopril anhydrousChEBI
ZestrilKegg
AcerbonHMDB
AcercompHMDB
AlaprilHMDB
CaraceHMDB
CipralHMDB
CiprilHMDB
CoricHMDB
InhibrilHMDB
InoprilHMDB
LinoprilHMDB
LinvasHMDB
LiprilHMDB
LisinalHMDB
LisinoprilumHMDB
LisiprilHMDB
LisorilHMDB
LisprilHMDB
LorilHMDB
LPRHMDB
LysinoprilHMDB
NopertenHMDB
NovatecHMDB
PresitenHMDB
PrinilHMDB
PrinivilHMDB
SinoprilHMDB
SinoprylHMDB
TensoprilHMDB
TensynHMDB
TersifHMDB
VivatecHMDB
Lisinopril maleate (1:1)HMDB
Lisinopril sulfate (1:2)HMDB
Chemical FormulaC21H31N3O5
Average Molecular Weight405.4879
Monoisotopic Molecular Weight405.226371117
IUPAC Name(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
Traditional Namelisinopril
CAS Registry Number83915-83-7
SMILES
NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
InChI Identifier
InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
InChI KeyRLAWWYSOJDYHDC-BZSNNMDCSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentDipeptides
Alternative Parents
Substituents
  • Alpha-dipeptide
  • N-acyl-alpha-amino acid
  • Proline or derivatives
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-l-alpha-amino acid
  • Alpha-amino acid amide
  • Alpha-amino acid
  • Alpha-amino acid or derivatives
  • L-alpha-amino acid
  • N-acylpyrrolidine
  • Pyrrolidine carboxylic acid
  • Pyrrolidine carboxylic acid or derivatives
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Dicarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Amino acid or derivatives
  • Carboxamide group
  • Amino acid
  • Organoheterocyclic compound
  • Secondary amine
  • Azacycle
  • Carboxylic acid
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Primary aliphatic amine
  • Organic oxide
  • Organic nitrogen compound
  • Organonitrogen compound
  • Carbonyl group
  • Organooxygen compound
  • Primary amine
  • Amine
  • Organic oxygen compound
  • Organopnictogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
Process
Role
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility97 mg/mLNot Available
LogPNot AvailableNot Available
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+Not Available189.656http://allccs.zhulab.cn/database/detail?ID=AllCCS00001275
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.22 g/LALOGPS
logP-1.2ALOGPS
logP-3.1ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.17ChemAxon
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area132.96 ŲChemAxon
Rotatable Bond Count12ChemAxon
Refractivity107.37 m³·mol⁻¹ChemAxon
Polarizability43.64 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+194.77931661259
DarkChem[M-H]-191.4631661259
AllCCS[M+H]+195.59832859911
AllCCS[M-H]-195.50432859911
DeepCCS[M+H]+196.77330932474
DeepCCS[M-H]-194.37730932474
DeepCCS[M-2H]-227.64230932474
DeepCCS[M+Na]+202.70630932474
AllCCS[M+H]+195.632859911
AllCCS[M+H-H2O]+193.332859911
AllCCS[M+NH4]+197.732859911
AllCCS[M+Na]+198.332859911
AllCCS[M-H]-195.532859911
AllCCS[M+Na-2H]-196.132859911
AllCCS[M+HCOO]-197.032859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
LisinoprilNCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O4336.1Standard polar33892256
LisinoprilNCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O3389.8Standard non polar33892256
LisinoprilNCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O3430.6Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Lisinopril,1TMS,isomer #1C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O3337.1Semi standard non polar33892256
Lisinopril,1TMS,isomer #2C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N[C@@H](CCC1=CC=CC=C1)C(=O)O3396.6Semi standard non polar33892256
Lisinopril,1TMS,isomer #3C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O3549.8Semi standard non polar33892256
Lisinopril,1TMS,isomer #4C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O3366.3Semi standard non polar33892256
Lisinopril,2TMS,isomer #1C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C3300.6Semi standard non polar33892256
Lisinopril,2TMS,isomer #2C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3407.0Semi standard non polar33892256
Lisinopril,2TMS,isomer #3C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C3256.6Semi standard non polar33892256
Lisinopril,2TMS,isomer #4C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C3443.5Semi standard non polar33892256
Lisinopril,2TMS,isomer #5C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C3264.7Semi standard non polar33892256
Lisinopril,2TMS,isomer #6C[Si](C)(C)N(CCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C3565.4Semi standard non polar33892256
Lisinopril,2TMS,isomer #7C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C3422.6Semi standard non polar33892256
Lisinopril,3TMS,isomer #1C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C3379.5Semi standard non polar33892256
Lisinopril,3TMS,isomer #1C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C3347.0Standard non polar33892256
Lisinopril,3TMS,isomer #1C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C4153.2Standard polar33892256
Lisinopril,3TMS,isomer #2C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3233.8Semi standard non polar33892256
Lisinopril,3TMS,isomer #2C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3215.6Standard non polar33892256
Lisinopril,3TMS,isomer #2C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C4580.6Standard polar33892256
Lisinopril,3TMS,isomer #3C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3483.7Semi standard non polar33892256
Lisinopril,3TMS,isomer #3C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3406.4Standard non polar33892256
Lisinopril,3TMS,isomer #3C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O4353.1Standard polar33892256
Lisinopril,3TMS,isomer #4C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3338.3Semi standard non polar33892256
Lisinopril,3TMS,isomer #4C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3338.2Standard non polar33892256
Lisinopril,3TMS,isomer #4C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C4304.5Standard polar33892256
Lisinopril,3TMS,isomer #5C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O3525.3Semi standard non polar33892256
Lisinopril,3TMS,isomer #5C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O3406.0Standard non polar33892256
Lisinopril,3TMS,isomer #5C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O4359.2Standard polar33892256
Lisinopril,3TMS,isomer #6C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C3350.6Semi standard non polar33892256
Lisinopril,3TMS,isomer #6C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C3364.6Standard non polar33892256
Lisinopril,3TMS,isomer #6C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C4274.6Standard polar33892256
Lisinopril,3TMS,isomer #7C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3551.2Semi standard non polar33892256
Lisinopril,3TMS,isomer #7C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3429.7Standard non polar33892256
Lisinopril,3TMS,isomer #7C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O4496.8Standard polar33892256
Lisinopril,4TMS,isomer #1C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C3490.5Semi standard non polar33892256
Lisinopril,4TMS,isomer #1C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C3422.5Standard non polar33892256
Lisinopril,4TMS,isomer #1C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C4012.4Standard polar33892256
Lisinopril,4TMS,isomer #2C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3335.2Semi standard non polar33892256
Lisinopril,4TMS,isomer #2C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3356.1Standard non polar33892256
Lisinopril,4TMS,isomer #2C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3936.4Standard polar33892256
Lisinopril,4TMS,isomer #3C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C3527.6Semi standard non polar33892256
Lisinopril,4TMS,isomer #3C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C3427.9Standard non polar33892256
Lisinopril,4TMS,isomer #3C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C4155.9Standard polar33892256
Lisinopril,4TMS,isomer #4C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C3536.1Semi standard non polar33892256
Lisinopril,4TMS,isomer #4C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C3442.7Standard non polar33892256
Lisinopril,4TMS,isomer #4C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C4125.9Standard polar33892256
Lisinopril,5TMS,isomer #1C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3573.3Semi standard non polar33892256
Lisinopril,5TMS,isomer #1C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3438.8Standard non polar33892256
Lisinopril,5TMS,isomer #1C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C3837.2Standard polar33892256
Lisinopril,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O3605.0Semi standard non polar33892256
Lisinopril,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N[C@@H](CCC1=CC=CC=C1)C(=O)O3661.7Semi standard non polar33892256
Lisinopril,1TBDMS,isomer #3CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O3746.9Semi standard non polar33892256
Lisinopril,1TBDMS,isomer #4CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O3629.7Semi standard non polar33892256
Lisinopril,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C3807.7Semi standard non polar33892256
Lisinopril,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3875.8Semi standard non polar33892256
Lisinopril,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C3820.6Semi standard non polar33892256
Lisinopril,2TBDMS,isomer #4CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C3916.1Semi standard non polar33892256
Lisinopril,2TBDMS,isomer #5CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C3840.3Semi standard non polar33892256
Lisinopril,2TBDMS,isomer #6CC(C)(C)[Si](C)(C)N(CCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C4034.3Semi standard non polar33892256
Lisinopril,2TBDMS,isomer #7CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C3934.9Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C4052.6Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C3868.2Standard non polar33892256
Lisinopril,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C4307.2Standard polar33892256
Lisinopril,3TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C4040.9Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3741.1Standard non polar33892256
Lisinopril,3TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C4587.7Standard polar33892256
Lisinopril,3TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O4194.0Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3921.6Standard non polar33892256
Lisinopril,3TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O4442.0Standard polar33892256
Lisinopril,3TBDMS,isomer #4CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C4114.3Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #4CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3852.7Standard non polar33892256
Lisinopril,3TBDMS,isomer #4CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C4426.1Standard polar33892256
Lisinopril,3TBDMS,isomer #5CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O4219.0Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #5CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O3909.6Standard non polar33892256
Lisinopril,3TBDMS,isomer #5CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O4439.9Standard polar33892256
Lisinopril,3TBDMS,isomer #6CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C4127.2Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #6CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C3859.9Standard non polar33892256
Lisinopril,3TBDMS,isomer #6CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C4394.1Standard polar33892256
Lisinopril,3TBDMS,isomer #7CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O4272.1Semi standard non polar33892256
Lisinopril,3TBDMS,isomer #7CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O3926.2Standard non polar33892256
Lisinopril,3TBDMS,isomer #7CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O4544.9Standard polar33892256
Lisinopril,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C4380.4Semi standard non polar33892256
Lisinopril,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C4055.4Standard non polar33892256
Lisinopril,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C4194.3Standard polar33892256
Lisinopril,4TBDMS,isomer #2CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C4302.1Semi standard non polar33892256
Lisinopril,4TBDMS,isomer #2CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3992.5Standard non polar33892256
Lisinopril,4TBDMS,isomer #2CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C4174.1Standard polar33892256
Lisinopril,4TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C4461.9Semi standard non polar33892256
Lisinopril,4TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C4061.7Standard non polar33892256
Lisinopril,4TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C4305.3Standard polar33892256
Lisinopril,4TBDMS,isomer #4CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C4459.3Semi standard non polar33892256
Lisinopril,4TBDMS,isomer #4CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C4051.3Standard non polar33892256
Lisinopril,4TBDMS,isomer #4CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C4273.0Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Lisinopril GC-MS (Non-derivatized) - 70eV, Positivesplash10-0006-9344000000-3673a7191e97a0ee02e02017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lisinopril GC-MS (2 TMS) - 70eV, Positivesplash10-0f6x-9201340000-bc9644b3a3a4109f37222017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lisinopril GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril Quattro_QQQ 10V, Positive-QTOF (Annotated)splash10-0a4r-0194100000-d9a47a283478b88bb1012012-07-25HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril Quattro_QQQ 25V, Positive-QTOF (Annotated)splash10-001i-9040000000-8d6d4ae6ba18da11e3362012-07-25HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril Quattro_QQQ 40V, Positive-QTOF (Annotated)splash10-001i-9000000000-77e20f7eb799eea58ab02012-07-25HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril LC-ESI-qTof , Positive-QTOFsplash10-01q0-0940000000-116994867a4e2c649c002017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril LC-ESI-qTof , Positive-QTOFsplash10-01q0-0940000000-116994867a4e2c649c002017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril 40V, Positive-QTOFsplash10-001i-9120000000-fd2acaa1eae37a6f7ba62021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril 10V, Positive-QTOFsplash10-0a4i-2010900000-67e85126826eedd63b6c2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril 20V, Positive-QTOFsplash10-053r-9052300000-d651e557fe1ae7eac4522021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril 10V, Negative-QTOFsplash10-0ik9-0900500000-85d2bfa23ac02fce017d2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril 40V, Negative-QTOFsplash10-03di-0900000000-b4cd463dbaeec149b8052021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lisinopril 20V, Negative-QTOFsplash10-03di-0900000000-c2a4ab9f5fb48e5480bf2021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 10V, Positive-QTOFsplash10-06ri-0229300000-236b576cdfc8112530c72017-07-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 20V, Positive-QTOFsplash10-03xu-4497000000-ad2ca7e02728a51b00512017-07-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 40V, Positive-QTOFsplash10-014i-9760000000-517501fe175444669d722017-07-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 10V, Negative-QTOFsplash10-0w29-0119600000-219bea00e0a247bc08882017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 20V, Negative-QTOFsplash10-03di-2429100000-404746794cb47e7eb6fc2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 40V, Negative-QTOFsplash10-03di-3920000000-b1093c7b1913ec8ec8d02017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 10V, Positive-QTOFsplash10-0a4i-0002900000-a76c25515295bb79175b2021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 20V, Positive-QTOFsplash10-0901-2395300000-cc32f663c74e5f0f33062021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 40V, Positive-QTOFsplash10-001i-9110000000-ccd25ccd5c2ff94948b42021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 10V, Negative-QTOFsplash10-0udi-0002900000-ce436e39fbead59af3f22021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 20V, Negative-QTOFsplash10-0ik9-3933500000-a236ac37e133779ee0ac2021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lisinopril 40V, Negative-QTOFsplash10-03dj-8910000000-db165b4504f7321c51e02021-09-24Wishart LabView Spectrum

NMR Spectra

Spectrum TypeDescriptionDeposition DateSourceView
Experimental 1D NMR1H NMR Spectrum (1D, 500 MHz, H2O, experimental)2012-12-05Wishart LabView Spectrum
Experimental 2D NMR[1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental)2012-12-05Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
  • Urine
Tissue Locations
  • Kidney
  • Pancreas
  • Skeletal Muscle
  • Testis
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00722
Phenol Explorer Compound IDNot Available
FooDB IDFDB022753
KNApSAcK IDNot Available
Chemspider ID4514933
KEGG Compound IDD00362
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkLisinopril
METLIN ID1009
PubChem Compound5362119
PDB IDNot Available
ChEBI ID43755
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Download (PDF)
General References
  1. Corradi HR, Schwager SL, Nchinda AT, Sturrock ED, Acharya KR: Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol. 2006 Mar 31;357(3):964-74. Epub 2006 Jan 31. [PubMed:16476442 ]
  2. Alves MF, Araujo MC, Juliano MA, Oliveira EM, Krieger JE, Casarini DE, Juliano L, Carmona AK: A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-converting enzyme activity. Braz J Med Biol Res. 2005 Jun;38(6):861-8. Epub 2005 Jun 1. [PubMed:15933779 ]
  3. Tashtoush BM, Alali FQ, Najib NM: Liquid chromatographic-mass spectrometric method for quantitative determination of lisinopril in human plasma. Pharmazie. 2004 Jan;59(1):21-4. [PubMed:14964416 ]
  4. Swaisland AJ: The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. J Hum Hypertens. 1991 Dec;5 Suppl 2:69-71. [PubMed:1665181 ]
  5. Lanzillo JJ, Stevens J, Dasarathy Y, Yotsumoto H, Fanburg BL: Angiotensin-converting enzyme from human tissues. Physicochemical, catalytic, and immunological properties. J Biol Chem. 1985 Dec 5;260(28):14938-44. [PubMed:2999099 ]
  6. Huang J, Xu Y, Liu F, Gao S, Guo Q: Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of lisinopril in human plasma. Rapid Commun Mass Spectrom. 2006;20(2):248-52. [PubMed:16345121 ]
  7. Sudoh T, Fujimura A, Shiga T, Tateishi T, Sunaga K, Ohashi K, Ebihara A: Influence of lisinopril on urinary electrolytes excretion after furosemide in healthy subjects. J Clin Pharmacol. 1993 Jul;33(7):640-3. [PubMed:8396158 ]
  8. Ranieri G, Andriani A, Lamontanara G, De Cesaris R: Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther. 1994 Sep;56(3):323-30. [PubMed:7924128 ]
  9. Haenni A, Reneland R, Andersson PE, Lind L, Lithell H: Skeletal muscle magnesium content is correlated with plasma glucose concentration in patients with essential hypertension treated with lisinopril or bendrofluazide. Am J Hypertens. 2002 Aug;15(8):735-8. [PubMed:12160198 ]
  10. Arakawa M, Murata Y, Rikimaru Y, Sasaki Y: Drug-induced isolated visceral angioneurotic edema. Intern Med. 2005 Sep;44(9):975-8. [PubMed:16258215 ]
  11. Donohoe JF, Kelly J, Laher MS, Doyle GD: Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med. 1988 Sep 23;85(3B):31-4. [PubMed:2844084 ]
  12. Donohoe JF, Laher M, Doyle GD, Long C, Glover DR, Cooper WD: Lisinopril treatment of hypertension in patients with impaired renal function. Gerontology. 1987;33 Suppl 1:36-41. [PubMed:2831115 ]
  13. Yuan AS, Gilbert JD: Time-resolved fluoroimmunoassay for the determination of lisinopril and enalaprilat in human serum. J Pharm Biomed Anal. 1996 May;14(7):773-81. [PubMed:8809701 ]
  14. Araujo MC, Melo RI, Del Nery E, Alves MF, Juliano MA, Casarini DE, Juliano L, Carmona AK: Internally quenched fluorogenic substrates for angiotensin I-converting enzyme. J Hypertens. 1999 May;17(5):665-72. [PubMed:10403610 ]
  15. Shionoiri H, Shigemasa T, Takasaki I: [Angiotensin-converting enzyme inhibitors: recent therapeutic aspect]. Nihon Rinsho. 1997 Aug;55(8):2067-74. [PubMed:9284425 ]

Enzymes

General function:
Involved in metallopeptidase activity
Specific function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety
Gene Name:
ACE
Uniprot ID:
P12821
Molecular weight:
149713.7
General function:
Involved in serine-type endopeptidase inhibitor activity
Specific function:
Angiotensin 1-7 is a ligand for the G-protein coupled receptor MAS1. Has vasodilator and antidiuretic effects. Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets
Gene Name:
AGT
Uniprot ID:
P01019
Molecular weight:
53153.7